.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Novel Concepts in the Management of Multiple Myeloma

EP. 1: Goals of Therapy for Symptomatic Myeloma

June 21st 2017

EP. 2: MRD Negativity in Multiple Myeloma

June 21st 2017

EP. 3: Risk Stratification for Myeloma

June 21st 2017

EP. 4: Optimal Timing for Transplantation in Myeloma

June 21st 2017

EP. 5: Maintenance Therapy for Multiple Myeloma

June 21st 2017

EP. 6: Antibodies for Relapsed/ Refractory Multiple Myeloma

June 21st 2017

EP. 7: Continuing IMiD Therapy after Myeloma Relapse

June 21st 2017

EP. 8: Sequencing Therapies in Multiple Myeloma

June 21st 2017

EP. 9: Immunotherapy for Multiple Myeloma

June 21st 2017

EP. 10: CAR T-Cell Therapy for Multiple Myeloma

June 21st 2017

EP. 11: Emerging Agents for Multiple Myeloma

June 21st 2017

EP. 12: Future Directions in Multiple Myeloma

June 21st 2017